MGRS — Monoclonal Gammopathy of Renal Significance

Kidney injury driven by MGUS-level M-proteins — AL amyloidosis, MGRS-associated MPGN, MIDD, C3G, and the principle that the clone must be treated even when it is small

Key Points

• MGRS is defined as any B-cell or plasma cell clone of MGUS magnitude that produces a monoclonal immunoglobulin directly causing kidney damage — even when the clone itself is too small to meet criteria for multiple myeloma, WM, or other established hematologic malignancy.
• The kidney biopsy is mandatory and central to MGRS diagnosis — it characterizes the pattern of renal injury (amyloid, monoclonal Ig deposits, complement-mediated, cast nephropathy) and, combined with immunofluorescence and electron microscopy, identifies the specific immunoglobulin component (kappa vs. lambda, heavy chain class).
• The most common MGRS entities are AL amyloidosis, monoclonal immunoglobulin deposition disease (MIDD — light chain or heavy chain), C3 glomerulopathy with monoclonal Ig (C3G-MGRS), and proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID).
• The therapeutic principle of MGRS is fundamentally different from MGUS surveillance: because the M-protein is directly causing organ damage, the clone must be treated regardless of its size — using myeloma-directed therapies (bortezomib-based, daratumumab-based regimens) to eliminate or suppress the nephrotoxic Ig-secreting clone.
• Early clone-directed treatment is essential — renal function at treatment initiation is the strongest predictor of renal outcome. Delay in diagnosis (often due to failure to perform kidney biopsy and clone testing) is the main driver of irreversible renal failure in MGRS.
• Kidney transplantation should not be performed until clone-directed therapy has achieved complete or very good partial response — without clone eradication, MGRS universally recurs in the transplanted kidney.

Concept, Pathogenesis, and Major Entities

**Why MGRS is not "just MGUS with kidney disease":** The term MGRS (coined by Leung N, et al., Blood 2012) was created to address a clinically critical gap: many patients present with significant kidney disease caused by an M-protein, but because the clone is small (M-protein kappa) misfold into β-pleated sheet fibrils that deposit in glomerular mesangium and walls, tubular basement membranes, and renal vessels. Congo red staining shows green birefringence under polarized light. The amyloid deposits progressively replace normal glomerular architecture, causing nephrotic syndrome (massive…

Diagnosis — Kidney Biopsy and Clone Characterization

**The kidney biopsy is required:** A kidney biopsy with light microscopy, immunofluorescence (IF), and electron microscopy (EM) is mandatory to: 1. Identify the pattern of glomerular, tubular, or vascular injury 2. Determine the nature of deposits (fibrillar vs. non-fibrillar; amyloid vs. non-amyloid) 3. Characterize the immunoglobulin components (kappa vs. lambda restriction; IgG vs. IgA vs. IgM; specific IgG subclass — IgG3 in PGNMID) 4. Guide treatment by identifying the target clone **Key biopsy findings by entity:** | Entity | LM | IF | EM | |---|---|---|---| | AL amyloidosis | Congo…

Clone-Directed Treatment and Renal Outcomes

**Treatment principle: treat the clone, not just the kidney:** Unlike MGUS (where the clone is watched), in MGRS the nephrotoxic M-protein must be eliminated or suppressed to halt renal progression. The treatment choice depends on the underlying cell lineage: **Plasma cell clone (most AL amyloidosis, LCDD, some PGNMID):** *Daratumumab-based regimens (first-line for transplant-ineligible or as initial therapy):* - Dara-CyBorD (daratumumab + cyclophosphamide + bortezomib + dexamethasone): the ANDROMEDA trial (NEJM 2021) demonstrated superiority over CyBorD alone in AL amyloidosis — 53%…